SCHEMBL20969731

SCHEMBL20969731

COc1ccc(CCN(c2nc3ccc(Br)cc3s2)C(C)c2ccc(C(=O)O)cc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KARS1 Q15046 1/20 0.46
LMNA P02545 2/20 0.43
MITF O75030 1/20 0.43
MAPT P10636 1/20 0.43
IDE P14735 1/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
FFAR1 O14842 1/20 0.40
POLB P06746 1/20 0.40
TAS2R14 Q9NYV8 2/20 0.39
WNT3A P56704 1/20 0.39
LPAR1 Q92633 1/20 0.39
LPAR5 Q9H1C0 1/20 0.39
GSK3B P49841 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2E1 P05181 1/20 0.38
CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20969680 0.93 KARS1 (0.46) KARS1LMNAMAPTMAPK1SMN1; SMN2
SCHEMBL20969664 0.90 PPARD (0.47) KARS1LMNAMAPTMEN1KMT2A
SCHEMBL20969586 0.90 PPARD (0.46) KARS1LMNAMAPTMAPK1HTT
SCHEMBL20969667 0.87 CSNK1D (0.49) KARS1LMNAMAPTMEN1KMT2A
SCHEMBL20969622 0.87 KARS1 (0.47) KARS1LMNAMAPTSMN1; SMN2MEN1
SCHEMBL20969683 0.85 KARS1 (0.47) KARS1LMNAMAPTSMN1; SMN2FFAR1
SCHEMBL20969737 0.84 KARS1 (0.46) KARS1MAPTFFAR1TAS2R14LPAR1
SCHEMBL20969716 0.84 KARS1 (0.46) KARS1LMNAMAPTMAPK1HTT
SCHEMBL20969597 0.84 KARS1 (0.65) KARS1LMNAMITFMAPTIDE
SCHEMBL20969604 0.82 KARS1 (0.44) KARS1MAPTFFAR1TAS2R14LPAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3483149-B1 BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME YUHAN CORP (KR) 2021-01-13 EP claimed
US-10383859-B2 Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same YUHAN CORPORATION (KR) 2019-08-20 US claimed
US-20190142809-A1 Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same YUHAN CORPORATION (KR) 2019-05-16 US claimed
EP-3483149-A1 BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME Yuhan Corporation (KR) 2019-05-15 EP claimed
EP-3483149-B1 BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME YUHAN CORP (KR) 2021-01-13 EP disclosed
US-10383859-B2 Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same YUHAN CORPORATION (KR) 2019-08-20 US disclosed
US-20190142809-A1 Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same YUHAN CORPORATION (KR) 2019-05-16 US disclosed
EP-3483149-A1 BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME Yuhan Corporation (KR) 2019-05-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190142809-A1 Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same ILK, SBDS, BDKRB1 KARS1 6/4885LMNA 619/4885MITF 181/4885
US-10383859-B2 Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same ILK, SBDS, BDKRB1 KARS1 6/4885LMNA 619/4885MITF 181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.